Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin.
The aim of this study was to determine the efficacy of using a high-efficiency particulate air (HEPA) filter air cleaning system, a demistifier, to reduce the potential risk of fugitive aerosol contact in health care personnel working with patients inhaling nebulized liposomal encapsulated SLIT (Sustained-release Lipid Inhalation Targeting) Cisplatin. Filters were used to sample platinum in the air outside the tent and from the tent's exhaust stream. Air collection was performed under three conditions: (1) during patient dosing (14 h of air collection); (2) immediately after the patient has left the demistifier tent (4 h of air collection); and (3) when 7 mL of drug product was nebulized to dryness in the tent without a patient being present. Filters were collected, and placed in an extraction solvent. Subsequently, the solvent was assayed for platinum content by inductively coupled plasma-mass spectrometry (ICP-MS). Platinum levels in the extraction solvent were indistinguishable from the blank controls for all conditions. Measured levels were below workplace exposure limits established for cisplatin by the Occupational Safety and Health Administration (i.e., 2 ng . (L(1)). In addition, the demistifier was able to effectively capture aerosolized SLIT Cisplatin following nebulization of 7 mL of drug product to dryness in the tent. The demistifier tent is effective at containing any nebulized liposomal encapsulated cisplatin during patient treatment. Importantly, because the tent's HEPA filtration system is effective at removing any nebulized liposomal cisplatin, the exhausted air, which is free of platinum, can be returned into the room with no additional ventilation precautions.
Wittgen
Bart P H
BP
Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands.
Kunst
Peter W A
PW
Perkins
Walter R
WR
Lee
Jin K
JK
Postmus
Pieter E
PE
D000336:Aerosols; D016902:Air Pollution, Indoor / Q000517:prevention & control*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage*; D004333:Drug Administration Routes; D005069:Evaluation Studies as Topic; D005374:Filtration / Q000379:methods; D001239:Inhalation; D008081:Liposomes / Q000737:chemistry*; D013058:Mass Spectrometry / Q000379:methods; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D014481:United States; D014489:United States Occupational Safety and Health Administration; D014691:Ventilation; D017132:Workplace
D000336:Aerosols; D000970:Antineoplastic Agents; D008081:Liposomes; D002945:Cisplatin